Patient preferences for reducing bowel adverse events following prostate radiotherapy

被引:3
|
作者
Mishra, Mark, V [1 ]
Thayer, Winter Maxwell [2 ,3 ]
Janssen, Ellen [4 ]
Hoppe, Bradford [5 ]
Eggleston, Caitlin [1 ]
Bridges, John F. P. [6 ]
机构
[1] Univ Maryland, Sch Med, Dept Radiat Oncol, Baltimore, MD 21201 USA
[2] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA
[3] Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA
[4] Ctr Med Technol Policy, Baltimore, MD USA
[5] Mayo Clin Florida, Dept Radiat Oncol, Tampa, FL USA
[6] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA
来源
PLOS ONE | 2020年 / 15卷 / 07期
关键词
DISCRETE-CHOICE EXPERIMENTS; LINEAR SCORING RULES; CONJOINT-ANALYSIS; REPORTED OUTCOMES; PROTON THERAPY; CANCER; WEIGHTS;
D O I
10.1371/journal.pone.0235616
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background The Extended Prostate Cancer Index Composite (EPIC) instrument is a commonly used patient reported outcome (PRO) tool in prostate cancer clinical trials. Summary scores for EPIC subscales are calculated by averaging patient scores for attributes (e.g., side effects), implying equal weighting of the attributes in the absence of evidence showing otherwise. Methods We estimated patient preferences for each of the attributes included in the bowel subscale of the EPIC instrument using best-worst (B-W) scaling among a cohort of men with prostate cancer. Patients were presented with multiple tasks in which they were asked to indicate which attribute they would find most and least bothersome at different levels of severity. Analysis utilized both (simple) B-W counts and scores to estimate patient preferences for each attribute as well as attribute levels. Results A total of 174 respondents from two institutions participated in the survey. Preference estimates for each of the five attributes included in the EPIC-26 bowel subscale showed wide variation preferences: 'losing control of bowel movements' was found to be the most bothersome attribute, with a B-W score of -0.48, followed by bowel urgency which also had negative B-W score (-0.04). Increased frequency of bowel movements was the least bothersome attribute, with a B-W score of +0.33, followed by bloody stools (+0.12), and pelvic/rectal pain (+0.06). Analysis of preference weights for attribute bother levels showed preference estimates be linear. Conclusions We provide novel evidence on patient preferences for side effect reduction following prostate radiotherapy. Within the bowel sub-scale of the EPIC-26 short form, we found that bowel incontinence was perceived to be the most bothersome treatment effect, while increased bowel frequency was least bothersome to patients.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] AN UPDATED REVIEW OF ADVERSE EVENTS RELATED TO THE INJECTION OF THE SPACEOAR® HYDROGEL SYSTEM BEFORE RADIOTHERAPY FOR PROSTATE CANCER
    Kotamarti, Srinath
    Schulman, Ariel
    JOURNAL OF UROLOGY, 2021, 206 : E113 - E113
  • [32] Letter to the Editor on "Major Complications and Adverse Events Related to Use of SpaceOAR Hydrogel for Prostate Cancer Radiotherapy"
    Santoro, Giuseppe
    Lombardo, Riccardo
    De Nunzio, Cosimo
    UROLOGY, 2024, 192 : 196 - 197
  • [33] Image-guided IMRT reducing urethral dose for prostate cancer - An evaluation of acute adverse events
    Takai, Y.
    Mitsuya, M.
    Narazaki, K.
    Sakayauchi, T.
    Britton, K. R.
    Ogawa, Y.
    Ariga, H.
    Takada, K.
    Jingu, K.
    Yamada, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S373 - S374
  • [34] A pilot randomised trial of online selfmonitoring of adverse events during pelvic radiotherapy using eRAPID (electronic patient self-Reporting of Adverse-events: Patient Information and aDvice)
    Holch, Patricia
    Absolom, Kate
    Gibson, Andrea
    Routledge, Jacki
    Rogers, Zoe
    Holmes, Marie
    Dickinson, Sarah
    Peacock, Rosemary
    Murphy, Anthony
    Henry, Ann
    Franks, Kevin
    Walker, Katrina
    McParland, Lucy
    Brown, Julia
    Velikova, Galina
    PSYCHO-ONCOLOGY, 2020, 29 : 9 - 9
  • [35] Adverse events following infliximab use
    Daly, W.
    Lakhoua, G.
    Aouinti, I.
    Zgolli, F.
    Daghfous, R.
    El Aidli, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 : 179 - 179
  • [36] Effectiveness of intraoral stents in reducing oral adverse events during radiotherapy for maxillary or nasal cavity malignant tumors
    Kawakami, Mao
    Ueda, Nobuhiro
    Yamaki, Kaori
    Aoki, Kumiko
    Wakai, Nobuhide
    Tamamoto, Tetsuro
    Asakawa, Isao
    Kirita, Tadaaki
    SUPPORTIVE CARE IN CANCER, 2024, 32 (03)
  • [37] Effectiveness of intraoral stents in reducing oral adverse events during radiotherapy for maxillary or nasal cavity malignant tumors
    Mao Kawakami
    Nobuhiro Ueda
    Kaori Yamaki
    Kumiko Aoki
    Nobuhide Wakai
    Tetsuro Tamamoto
    Isao Asakawa
    Tadaaki Kirita
    Supportive Care in Cancer, 2024, 32
  • [38] Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function: The patient's perspective
    Crook, J
    Esche, B
    Futter, N
    UROLOGY, 1996, 47 (03) : 387 - 394
  • [40] Adverse events following NPSA guidelines
    Slater, RM
    Shaw, J
    ANAESTHESIA, 2003, 58 (08) : 817 - 817